Delving into the Latest Updates on Nesiritide Recombinant with Synapse

Overview

Basic Info

Drug Type

Recombinant polypeptide

Synonyms

BNP, Brain natriuretic peptide, Brain natriuretic peptide 32

+ [11]

Target

NPRA

Action

agonists

Mechanism

NPRA agonists(Natriuretic peptide receptor 1 agonists)

Therapeutic Areas

Cardiovascular DiseasesRespiratory DiseasesUrogenital Diseases+ [1]

Active Indication-

Inactive Indication

Acute congestive heart failureAcute decompensated heart failureAcute Kidney Injury+ [15]

Originator Organization

Johnson & Johnson

Active Organization-

Inactive Organization

Scios, Inc.

Chengdu Shengnuo Biotechnology Co., Ltd.

Xian-Janssen Pharmaceutical Ltd.

+ [4]

License Organization

Scios, Inc.

Johnson & Johnson

Drug Highest PhaseWithdrawn

First Approval Date

United States (10 Aug 2001),

Acute decompensated heart failure

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 37334

Source: *****

The aims of this study were to assess the effects of resveratrol‐loaded nanoparticles (RLNP) on follicular survival, stromal integrity and activity of endogenous free‐radical scavengers in bovine ovarian tissues cultured in vitro. Ovarian cortical slices were incubated in α‐MEM + alone or supplemented with 0.2, 2.0 or 20.0 μM RLNP, blank nanoparticles (BNP) or free resveratrol (20.0 μM) for 6 days at 38.5°C and 5% CO 2 . Follicular integrity, number of stromal cells, density of collagen fibres, levels of thiol and activity of free‐radical scavengers (glutathione peroxidase [GPX], superoxide dismutase [SOD] and catalase [CAT]) were evaluated in tissues cultured in the different treatments. The data showed that ovarian cortex cultured with 20.0 μM free resveratrol or RLNP, in all tested concentrations, had a reduced rate of morphologically intact follicles in relation to uncultured controls ( p < 0.05). The RLNP (0.2, 2.0 or 20.0 μM) and BNP increased the proportion of growing follicles and stromal cell numbers ( p < 0.05). Collagen fibre levels decreased in tissues cultured with 0.2 or 2.0 μM RLNP compared to uncultured controls, but remained greater than those seen in ovarian cortex cultured in other treatments ( p < 0.05). Free resveratrol increased CAT and GPX activity, while RLNP reduced activity of SOD and GPX ( p < 0.05). In conclusion, RLNP improved follicle survival and growth, preserved stromal tissue and modulated the activity of free‐radical scavengers in bovine ovarian slices cultured in vitro.

01 Jan 2026·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Article

Author: Li, Shenyu ; Xiao, Lingyun ; Zhang, Yunyi ; Ding, Yufeng ; Lai, Xiyuan ; Peng, Zhangwen ; Lv, Jiawei ; Wang, Xiongjun ; Zhao, Chao ; Guo, Manna ; Zhou, Yulu ; Deng, Yang ; Liang, Shu ; Li, Zun ; Liu, Jin ; Liao, Wenyi

While the enhanced permeability of psoriatic skin facilitates topical delivery, it also poses challenges in drug retention and systemic absorption. To address these limitations, we designed a tunable nanocomposite hydrogel composed of poly(lactic acid)-hyperbranched polyglycerol-based bioadhesive nanoparticles (BNPs), carboxymethyl chitosan (CMCS), and chitooligosaccharide (COS), which enables on-demand drug delivery with deep epidermal retention and sustained release. The hydrogel's degradation rate is controlled by component ratios, permitting tunable degradation and sustained nanoparticle release for up to 7 days. During degradation, it gradually releases entrapped water and non-adhesive BNP/COS. The released water increases skin hydration from 9 % to 20 %, promoting deeper nanoparticle penetration. Once inside, COS diffuses away, while BNPs adhere to deep epidermal layers, thereby ensuring site-specific and sustained celastrol (Cel) release via a degradation-penetration-adhesion mechanism. The system achieved ~80 % cumulative Cel release over 4 days in vitro and demonstrated prolonged retention in psoriatic lesions, with >75 % of BNPs remaining after 1 day and persisting for over 4 days. In addition, the synergistic anti-inflammatory effects of Cel and COS further enhanced therapeutic efficacy. A single dose of Cel/BNP/CMCS/COS hydrogel reduced the Psoriasis Area and Severity Index (PASI) and skin thickness by over 60 % within 3 days in the imiquimod-induced psoriasis model.

01 Nov 2025·RESPIROLOGY

NT ‐ proBNP and BNP Testing in Pulmonary Arterial Hypertension: Point‐of‐Care and Remote Monitoring

Article

Author: Strickland, Scarlett ; Middleton, Jennifer T. ; Watson, Lisa ; Thompson, A. A. Roger ; Wilshaw, Heather ; Roman, Stefan ; Lewis, Robert A. ; Hameed, Abdul ; Zafar, Hamza ; Holt, Laura ; Oakes, Eleanor ; Condliffe, Robin ; Durrington, Charlotte ; Smith, Ian ; Elliot, Charlie A. ; Fairman, Alexandra ; Hitchcock, Felicity ; Charalampopoulos, Athanasios ; Turton, Helena A. ; Woodrow, Iain ; Salisbury, Thomas ; Ablott, Jenna ; Lawrie, Allan ; Rothman, Alex M. K. ; Hurdman, Judith A. ; Battersby, Christian ; Hamilton, Neil ; Kiely, David G. ; Roddis, Chloe ; Armstrong, Iain

ABSTRACT:

Background and Objectives:

Brain natriuretic peptide (BNP) and N‐terminal prohormone of BNP (NT‐proBNP) are important biomarkers in pulmonary arterial hypertension (PAH). However, results are rarely available at the time of clinical assessment. The reliability of NT‐proBNP/BNP point‐of‐care tests (POCT) in PAH patients and the stability of NT‐proBNP in posted blood samples, to simulate remote monitoring, was investigated.

Methods:

Group 1 PAH patients were prospectively recruited. A sample of 40 was required to demonstrate an intraclass correlation coefficient (ICC) of 0.94 with a 95% confidence interval width of < 0.1 for agreement between POCT and the laboratory standard. Blood samples were taken at two time‐points for laboratory and POCT NT‐proBNP/BNP. Separate samples were returned to the laboratory by post and some samples were assessed pre‐ and post‐exercise assessing the impact of exercise.

Results:

Forty‐one patients were enrolled with 56 study visits. NT‐proBNP laboratory and POCT ( n = 50) provided equivalent test results (Passing–Bablok slope = 1.08, CI = 0.97–1.19, intercept = 18.22, CI = −41.6 to 4.5) and ICC = 0.97. However, laboratory and POCT BNP ( n = 49), showed non‐equivalence (Passing–Bablok slope = 1.24, CI 1.11–1.31, intercept = −5.11, CI = −9.4 to −0.46), ICC = 0.96. POCT NT‐proBNP/BNP correctly classified 92% and 86% of cases, respectively against COMPERA 2.0 4‐risk‐strata thresholds. NT‐proBNP postal laboratory samples and immediately processed NT‐proBNP laboratory samples showed good agreement and exercise had no clinically significant effect on NT‐proBNP/BNP results. Laboratory BNP identified fewer patients as high risk compared to NT‐proBNP. BNP and NT‐proBNP risk status agreed at only 57% of visits ( p < 0.0009).

Conclusions:

These data support the use of POCT NT‐proBNP as a rapidly accessible and reliable alternative in clinical settings and highlight the potential of NT‐proBNP for remote monitoring via posted samples.

Trial Registration:

ClinicalTrials.gov registration: NCT05421949image

2

News (Medical) associated with Nesiritide Recombinant

19 Oct 2023

·www.sciencedaily.com

BNP peptide a culprit in eczema

Researchers have pinpointed a particular peptide's role in activating atopic dermatitis, or eczema. The work could lead to more effective treatments for the condition. Researchers from North Carolina State University have pinpointed a particular peptide's role in activating atopic dermatitis, or eczema. The work could lead to more effective treatments for the condition. Atopic dermatitis (AD) is a skin condition characterized by itching, irritated and thickened skin at the site of the irritation. The brain natriuretic peptide (BNP) is a peptide, or short chain of amino acids, that is elevated in patients with AD. "BNP is expressed in sensory neurons, the neurons responsible for conveying sensation to the brain via the spinal cord," says Santosh Mishra, associate professor of molecular biomedical sciences at NC State and corresponding author of the work. "We know from previous work that BNP helps translate the sensation of itch from the skin to the brain. In this work we wanted to see if BNP was involved in activating AD." In a chemically induced mouse model of AD, the researchers saw that mice without BNP did not exhibit the thickened or irritated skin commonly associated with AD, and their itching was reduced compared with control mice who did have BNP. "The results show that BNP likely plays a role in itch activation," Mishra says. "We next looked at BNP's relationship to periostin, to see if we could determine how that activation takes place." Periostin is a protein that can interact with sensory neurons in skin to activate itch response. It is produced in skin cells called keratinocytes and fibroblasts. Keratinocytes in turn, have receptors for BNP, which are called NPR1 receptors. When the BNP receptors are activated, periostin is produced and itch can be turned on. "But the interesting thing here is that the sensory neurons are the activator," Mishra says. The neuron releases BNP, which activates keratinocytes with the NPR1 receptor, which then release the periostin. "This work shows that peripheral neurons, not just central neurons, are playing a role in AD -- it begins in the sensory neurons, and cascades from there," Mishra adds. "It also points to some potential therapeutic strategies, such as blocking BNP's ability to bind to NPR1 receptors in the skin." The research appears as a letter to the editor in the Oct. 11 issue of the Journal of Investigative Dermatology. The work was supported by the National Institutes of Health under grant number 1R56AR077692-01. NC State undergraduate student Junho Yu, former NC State undergraduate student Nidha Williams, and NC State postdoctoral research scholar Joshua Wheeler, also contributed to the work.

26 Apr 2023

·www.prnewswire.com

The Role of Natriuretic Peptides in the Diagnosis and Management of Heart Failure Discussed in New Joint Scientific Statement by the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, and Japanese Heart Failure Society

ROCKVILLE, Md., April 26, 2023 /PRNewswire/ -- The Heart Failure Society of America (HFSA), the Heart Failure Association of the European Society of Cardiology (HFA-ESC) and the Japanese Heart Failure Society (JHFS) announced today a joint scientific statement on Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure. Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP), are internationally used as a biomarker for diagnosis and management in adults with heart failure (HF). In addition, natriuretic peptide biomarker data can be important in risk stratification of heart failure prognosis. In addition to biomarker data, implementation of an oral angiotensin receptor neprilysin inhibitor (ARNI) has increased healthcare professionals' awareness of natriuretic peptides as an important therapeutic agent. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure scientific statement aims to provide a framework and expert recommendations to healthcare professionals on the diagnosis and management of HF and focuses on the following areas: History and basic research: discovery, production, and cardiovascular protection Diagnostic and prognostic biomarkers: acute HF, chronic HF, inclusion/endpoint in clinical trials, and natriuretic peptides-guided therapy Therapeutic use: nesiritide (BNP), carperitide (ANP), and sacubitril (neprilysin inhibitor [combined with an angiotensin receptor blocker]), and Gaps in knowledge and future directions Standardized screening for HF remains challenging because of the heterogeneity of risk factors across different patient populations. Natriuretic peptides are recommended for initial diagnosis of HF as noted in the 2022 ACC/AHA/HFSA Guideline for the Management of HF, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF, and JCS2017/JHF2017 Guideline on diagnosis and treatment of acute and chronic HF. "There are several differences in the statements among HF Societies regarding the use of natriuretic peptides as biomarkers for risk stratification and prevention. The scientific statement provides up-to-date perspectives and guidance that healthcare professionals can use to navigate and provide the best care for their patients with HF," Nancy Albert, PhD, CCNS, CHFN; co-chair and co-author representing HFSA in the Trilateral International Consensus Conference (TICC) said. The joint scientific statement on natriuretic peptides was developed by the TICC, a collaboration of HFSA, JHFS and HFSA-ESC. The TICC 2021 was hosted by the JHFS and was chaired by Hiroyuki Tsutsui, President of the JHFS, with Nancy M. Albert (HFSA) and Andrew Coats (HFA-ESC) serving as co-chairs. The Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure scientific statement will jointly publish on Monday 17 April at 9:00 AM EDT in the Journal of Cardiac Failure, the official journal of the HFSA and the JHFS, and the European Journal of Heart Failure, the official journal of the HFA-ESC. DOI: 10.1016/j.cardfail.2023.02.009 To receive a copy of the manuscript in advance of the embargo, contact [email protected]. About the Heart Failure Society of America The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org. About the Heart Failure Association of the European Society of Cardiology As the world's largest heart failure association, the Heart Failure Association of the ESC prioritizes patient management and awareness of heart failure as a global health problem. HFA-ESC's mission is to improve quality of life and longevity through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research. Learn more online. About the Japanese Heart Failure Society In response to the increased interest in heart failure, based on the basic studies on its mechanisms and clinical trials, the Japanese Heart Failure Society (JHFS) was established in 1996. The first General and Scientific Meeting of the JHFS was held in October 1997 at the Kyoto International Conference Center. The number of members increased from 900 to approximately 4000 in 2020. The vision of JHFS is to enrich the happy life of the patients and their families through investigating the basic pathophysiology of heart failure, and developing the effective and efficient diagnosis, prevention and treatment strategies. About the Journal of Cardiac Failure The Journal of Cardiac Failure (JCF) publishes the highest quality science in the field of heart failure with a focus on diversity, equity, and inclusion, mentorship, multidisciplinary partnerships, and patient-centeredness. Published papers span original investigator-initiated work to state-of-the-art reviews, guidelines and scientific statements, expert perspectives, early career and trainee spotlight pieces, patient and patient-partner narratives. JCF also emphasizes the power of language and prioritizes innovative approaches to dissemination of published work to reach and impact the broader heart failure community. For more information, visit onlinejcf.com. About the European Journal of Heart Failure The European Journal of Heart Failure (EJHF) is dedicated to the advancement of knowledge in the field of heart failure management. The journal publishes reviews and editorials to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as clinical, social and population sciences all form part of the discipline. Visit EJHF online. Media Contact: Laura Poko: Director of Marketing and Communications, Heart Failure Society of America, 301-798-4493, ext. 226 [email protected] Olivia Seward: Associate Director Communication, European Society of Cardiology, +33 (0)4 89 87 20 10, [email protected] SOURCE Heart Failure Society of America

100 Deals associated with Nesiritide Recombinant

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Nesiritide Recombinant	C01DX19	DB04899

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute decompensated heart failure	United States	Scios LLC	10 Aug 2001

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Coronary Artery Disease	Phase 3	-	Scios, Inc.	17 Sep 2007
Pulmonary Disease, Chronic Obstructive	Phase 3	Australia	Janssen-Cilag Pty Ltd.	01 Sep 2007
Cardiomyopathies	Phase 3	-	Scios, Inc.	01 Jan 2001
Dyspnea, Paroxysmal	Phase 3	-	Scios, Inc.	01 Jan 2001
Acute congestive heart failure	Phase 3	-	Scios, Inc.	01 Oct 1999
Decompensated chronic heart failure	Phase 3	-	Scios, Inc.	01 Oct 1999
Heart failure NYHA class IV	Phase 3	-	Scios, Inc.	01 Aug 1998
Chronic congestive heart failure	Phase 3	-	Scios, Inc.	01 Oct 1996
Heart Failure	Phase 3	-	Scios, Inc.	01 Oct 1996
Ventricular Dysfunction, Left	Phase 2	United States	Scios, Inc.	01 Mar 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00281671 (CTgov)	Phase 1/2	Heart Defects, Congenital	9	Placebo (Placebo)	kogpbyvsdt(gxncrjsphj) = urdyugmuxz xhqmeckyub (vqszgbptii, qpzkrzmeci - eqctdkjbtd) View more	-	27 Aug 2020
				nesiritide (Nesiritide)	kogpbyvsdt(gxncrjsphj) = rphsklydef xhqmeckyub (vqszgbptii, aqwbistbyq - bwjkripehk) View more
NCT00543309 (CTgov)	Phase 2	Heart Defects, Congenital	106	nesiritide (I- Nesiritide)	olehbswtiy(chpihhtcxb) = roygefujtv hoagnwtfew (xwpcoiotom, ijmkrpjdyr - gnguerfoxo) View more	-	25 Jun 2018
				milrinone (II- Milrinone)	olehbswtiy(chpihhtcxb) = njyzjwwgiy hoagnwtfew (xwpcoiotom, maepvsnpgf - wpedcrqlwd) View more
NCT00475852 (ASCEND-HF, Pubmed \| Circ Heart Fail)	Phase 3	Acute decompensated heart failure	7,141	Nesiritide (High enrolling sites)	hxapqcerby(nfphupwnyb): hazard ratio = 0.99 (95% CI, 0.98 - 1.01) View more	-	01 Sep 2016
				Nesiritide (Low enrolling sites)
NCT00475852 (ASCEND-HF, Pubmed \| BMJ Open)	Phase 3	Heart Failure	1,068	Nesiritide (Self-presentation)	vlbrgijdcv(ndzbunkfur) = ivoeiyfzrv djjozuowby (lsdnjyecau ) View more	-	17 Mar 2016
				Nesiritide (Ambulance)	vlbrgijdcv(ndzbunkfur) = zsfjdueemo djjozuowby (lsdnjyecau ) View more
NCT00475852 (ASCEND-HF, Pubmed \| J Am Heart Assoc)	Phase 3	Heart Failure \| Atrial Fibrillation	7,007	nesiritide (Patients with AF)	wwoftcnqkn(ravwstlbvl) = wvkiojzewf iestcdehox (hkmcedaccp )	-	24 Aug 2015
				nesiritide (Patients without AF)	wwoftcnqkn(ravwstlbvl) = tfgbjkroes iestcdehox (hkmcedaccp )
NCT01544998 (CTgov)	Phase 1/2	Depressive Disorder \| Heart Failure \| Renal Insufficiency	43	Tadalafil+Nesiritide (Tadalafil Plus Nesiritide)	xyksoywkgh(pfvhkfrhsu) = tzcadxlhcx mtbdlihqbo (oruutvvfwt, 161.8) View more	-	04 Mar 2015
				Placebo+Tadalafil (Tadalafil Plus Placebo)	xyksoywkgh(pfvhkfrhsu) = dggmukjlvo mtbdlihqbo (oruutvvfwt, 86.5) View more
NCT00475852 (ASCEND-HF, Pubmed \| Circulation)	Phase 3	Acute decompensated heart failure	7,141	Nesiritide	bndvocsrip(yifojexvay) = auxxkfmkgg yklcyyhpaj (dpqkzryezm ) View more	-	16 Sep 2014
				Placebo	bndvocsrip(yifojexvay) = xukhhfexrj yklcyyhpaj (dpqkzryezm ) View more
NCT00573144 (Believe II, CTgov)	Phase 2	Anterior Wall Myocardial Infarction \| Acute myocardial infarction	59	Placebo (Placebo)	jibodqxnvk(aoplhucpex) = wnayrjqtja zpixvgjqrg (usxhaqeaqv, 58) View more	-	09 Sep 2014
				Nesiritide (Nesiritide)	jibodqxnvk(aoplhucpex) = ccqqmyojku zpixvgjqrg (usxhaqeaqv, 31) View more
NCT01132846 (ROSE/RED ROSE \| ROSE AHF \| ROSE, CTgov)	Phase 2	Dyspnea \| Heart Failure	360	Dopamine (Low Dose Dopamine)	vadiylruaf(nsdzfxhaja) = gaemlmrpzb uhmxydslul (vcqfyybqci, .32) View more	-	21 Aug 2014
				Placebo (Placebo)	vadiylruaf(nsdzfxhaja) = xcqkwlhuxy uhmxydslul (vcqfyybqci, .27) View more
NCT01836809 (CTgov)	Phase 4	Cardio-Renal Syndrome	2	nesiritide (Total Artificial Heart)	ochghuwggl(juqqmjhaxs) = baetmjgzsf liyvlqbotn (dqozvyjveu, ubgnicgawl - vkwpwdhnqh) View more	-	18 Aug 2014
				placebo (Total Artificial Heart: Placebo)	ochghuwggl(juqqmjhaxs) = ofoejjqnad liyvlqbotn (dqozvyjveu, johbmkcepk - birlrtmwxj) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data